Evidence map›Paper›PMID 41635761›Full record

ArticleRSC advances2026

A near-infrared-controlled and logic gate sensing platform for the sensitive and specific detection of dual miRNAs.

Xinqin He, Mengjie Yang, Xia Zhang, Bin Qiu, Hong Jiang

Abstract read
In one paragraph

Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xinqin HeDepartment of Obstetrics and Gynecology, The First Affiliated Hospital of Fujian Medical University Fuzhou 350005 China.
Mengjie YangDepartment of Obstetrics and Gynecology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University Xiamen 361021 China.ORCID https://orcid.org/0000-0002-5234-2518
Xia ZhangDepartment of Obstetrics and Gynecology, The First Affiliated Hospital of Fujian Medical University Fuzhou 350005 China.
Bin QiuCollege of Chemistry, Fuzhou University Fuzhou 350108 China summer328cn@163.com.ORCID https://orcid.org/0000-0003-2011-3320
Hong JiangDepartment of Reproductive Center, The First Affiliated Hospital of Fujian Medical University Fuzhou 350005 China drjiang2025@163.com.ORCID https://orcid.org/0009-0005-0044-8416

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Early detection of endometrial cancer remains challenging because of the lack of sensitive and specific diagnostic methods. This study develops a near-infrared (NIR)-activatable sensing platform with an AND logic gate to simultaneously detect miR-21 and miR-155, two promising endometrial cancer biomarkers. The sensing platform integrates acid-sensitive zeolitic imidazolate framework-8 (ZIF-8)-coated upconversion nanoparticles (UCNP@ZIF-8) with ternary DNA strands, consisting of a BHQ2-modified long strand (S2), a Cy5-labelled short strand (S3), and a photocleavable switch-bearing strand (S1). In a weakly acidic environment, the ZIF-8 shell decomposes to release UCNPs and DNA strands. Under 808 nm excitation, the UCNPs convert NIR light to ultraviolet or visible emission, cleaving the photocleavable linkers on S1 and exposing the toehold domain. The target miRNAs subsequently initiate a toehold-mediated strand displacement reaction, simultaneously displacing S1 and S3, thereby restoring Cy5 fluorescence. The biosensor demonstrated excellent sensitivity, with detection limits of 0.28 nM for miR-21 and 0.35 nM for miR-155. Validation in serum samples revealed recovery rates of 92-103.08%, confirming its potential for clinical application in complex biological environments.

Identifiers

PMID41635761
PMCPMC12863247

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.